STAT3 and colorectal carcinoma: Hypoxic CRC patients may also benefit from sarilumab (IL-6 receptor (IL-6R)-blocking antibody), which is approved for treatment of Castleman syndrome by the FDA (38), since IL6/JAK/STAT3 pathway was closely associated with M2 macrophages although their implication in oncogenesis was less well characterized (24).